SCIENCE@home

Impact of Non-Toxic Metabolic Disruptors on Overall Survival and One Year Survival Rate in Exocrine Pancreatic Cancer. Update and Observations on Early Intervention

Prieto Gratacós E,Redal Ma,A. R.

Published 2019 in Oncology Research and Reviews

ABSTRACT

Introduction: Despite the fact that exocrine pancreatic cancer ranks as one of the most lethal forms of neoplasm, with a mortality/incidence rate nearing 98% in both industrialized and developing countries, little improvements has been made in recent decades by means of standard cytotoxic treatment. New effective and non-toxic methods are badly needed. Objective: To further evaluate the therapeutic impact of the method of competitive inhibition of tumor enzymatic activity by means of structural analogs (CISA protocol) on pancreatic cancer patients, and to assess the robustness of our previous conclusions considering an improved N value. Methods: The clinical outcome of 27 pancreatic cancer patients undergoing the CISA protocol (Competitive Inhibition with Structural Analogs), with no other concomitant therapy, were tabulated to determine overall survival and one-year survival rates. Tumor remission and progression-free survival were also evaluated. Measurements of the effect size were chosen over statistical significance as a means of evaluation of relevant data. Results: Following up on a previous Randomized Controlled Clinical Trial on the metabolic therapy of exocrine pancreatic cancer, these authors have found that the one-Year Survival rate (YS) of our study (N=27) has remained above 70%, while overall survival (OS) increased to 27,82 (4-76) months. The YS of the subset of patients with no metastasis at the time of diagnosis stayed at 100%. It has become apparent that OS of the treated group has come to be 5.6 times the OS reported worldwide, which stands at 4,5 (3-6) months. Conclusion: The magnitude of the observed effects suggests that the metabolic therapy of pancreatic cancer allows for a substantial increase in both parameters of survival, particularly in patients with no metastatic lesions at T 0 .

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-39 of 39 references · Page 1 of 1

CITED BY